A randomized clinical trial demonstrated that bioptron light therapy efficiently minimizes patients’ pain expressed on visual analogue scale (VAS), heals soft tissue around the implant, and reduces inflammatory indicators in patients diagnosed with peri-implant mucositis. Gianna Maria Nardi et al. aimed to assess the effectiveness of mechanical debridement therapy plus bioptron hyperlight therapy for reducing periodontal indexes and for lowering the total oxidative salivary stress.

Overall, 40 patients suffering from peri-implant mucositis were recruited and randomly segregated into study group and control group. Patients in the study group were treated with mechanical debridement therapy plus bioptron hyperlight therapy and patients in control group were treated with mechanical debridement therapy alone.

The duration of study was six months. At T0, T1 (14 days), T2 (1 month), and T3 (6 months), recording of data on pain relief, probing pocket depth (PPD), bleeding on probing (BoP), and plaque index (PI) was done. Evaluation of group differences was done utilizing Pearson's Chi-squared test of homogeneity and Student's t-test. Compared to the control group, a reduction in PI and PPD was observed in the study group at the T0 and T1 and during the overall observation time.

A remarkably faster reduction in VAS pain and BoP was observed in the study group than in the control group. No significant differences in salivary antioxidant test changes were observed at any time interval. There was no correlation of patients' gender and smoking habit with the clinical outcomes. Hence, the use of bioptron hyperlight therapy as an adjunct to the standard of care significantly improves clinical parameters related to peri-implant mucositis.